title: Immunogenicity of Vi capsular polysaccharide vaccine evaluated for three years in Korea.
abstract: The immunogenicity of a single dose of Salmonella typhi(S.typhi) Vi capsular polysaccharide(CPS) vaccine was evaluated before, and at 1, 3, 12, and 36 months after vaccination. Eighty-five adults(20-28 years of age) and sixty-four children(8-16 years of age) received a single dose of 25 micrograms Vi CPS vaccine intramuscularly, and antibody titers to Vi CPS were measured by passive hemagglutination. Of 149 vaccinees, 138(92.6%) showed seroconversion at 1 month after vaccination, and then 138 out of 141(97.9%) did at 3 months. Of 137 vaccinees, 116(84.7%) maintained a persistent rise in Vi antibody titer 12 months after vaccination, and 55 out of 100(55.0%) had a 4-fold or greater rise at 36 months. No significant adverse reactions were observed. Booster injection may be needed 3-5 years after vaccination.
authors: Department of Internal Medicine and Pediatrics, Catholic University Medical College, Seoul, Korea.
authors: Y R
authors: YR
authors: Kim
authors: J H
authors: JH
authors: Yoo
authors: J K
authors: JK
authors: Hur
authors: J H
authors: JH
authors: Kang
authors: W S
authors: WS
authors: Shin
authors: M W
authors: MW
authors: Kang
mesh_terms: D000293:Adolescent; D000328:Adult; D000907:Antibodies, Bacterial / Q000097:blood; D000942:Antigens, Bacterial / Q000276:immunology; D002648:Child; D005069:Evaluation Studies as Topic; D006801:Humans; D011135:Polysaccharides, Bacterial / Q000276:immunology*; D012485:Salmonella typhi / Q000276:immunology*; D014435:Typhoid Fever / Q000517:prevention & control; D014436:Typhoid-Paratyphoid Vaccines / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*
chemical_list: D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D011135:Polysaccharides, Bacterial; D014436:Typhoid-Paratyphoid Vaccines; C054154:capsular polysaccharide, Salmonella